JP2022531552A - プラスモジウムスポロゾイト周囲タンパク質に結合する抗体、及びその使用 - Google Patents

プラスモジウムスポロゾイト周囲タンパク質に結合する抗体、及びその使用 Download PDF

Info

Publication number
JP2022531552A
JP2022531552A JP2021561902A JP2021561902A JP2022531552A JP 2022531552 A JP2022531552 A JP 2022531552A JP 2021561902 A JP2021561902 A JP 2021561902A JP 2021561902 A JP2021561902 A JP 2021561902A JP 2022531552 A JP2022531552 A JP 2022531552A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
variable region
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021561902A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022531552A5 (https=
Inventor
ダヴィデ・コルティ
ルカ・ピッコリ
カーチャ・フィンク
エリザベッタ・カメロニ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vir Biotechnology Inc
Original Assignee
Vir Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vir Biotechnology Inc filed Critical Vir Biotechnology Inc
Publication of JP2022531552A publication Critical patent/JP2022531552A/ja
Publication of JP2022531552A5 publication Critical patent/JP2022531552A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2021561902A 2019-04-30 2020-04-30 プラスモジウムスポロゾイト周囲タンパク質に結合する抗体、及びその使用 Pending JP2022531552A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2019/061135 2019-04-30
PCT/EP2019/061135 WO2020221451A1 (en) 2019-04-30 2019-04-30 Antibodies binding to plasmodium circumsporozoite protein and uses thereof
PCT/EP2020/062167 WO2020221910A1 (en) 2019-04-30 2020-04-30 Antibodies binding to plasmodium circumsporozoite protein and uses thereof

Publications (2)

Publication Number Publication Date
JP2022531552A true JP2022531552A (ja) 2022-07-07
JP2022531552A5 JP2022531552A5 (https=) 2023-04-24

Family

ID=66429360

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021561902A Pending JP2022531552A (ja) 2019-04-30 2020-04-30 プラスモジウムスポロゾイト周囲タンパク質に結合する抗体、及びその使用

Country Status (13)

Country Link
US (1) US20230084102A1 (https=)
EP (1) EP3962513A1 (https=)
JP (1) JP2022531552A (https=)
KR (1) KR20220004055A (https=)
CN (1) CN114206921B (https=)
AU (1) AU2020266283A1 (https=)
BR (1) BR112021016341A2 (https=)
CA (1) CA3130805A1 (https=)
EA (1) EA202192930A1 (https=)
IL (1) IL285282A (https=)
MX (1) MX2021013252A (https=)
SG (1) SG11202108585QA (https=)
WO (2) WO2020221451A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021257665A1 (en) * 2020-06-19 2021-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibody that targets a conserved site on the plasmodium falciparum circumsporozoite protein
WO2022251585A2 (en) * 2021-05-28 2022-12-01 David Weiner Dna antibody constructs for use against plasmodium parasites
CN117467005A (zh) * 2023-11-15 2024-01-30 深圳重链生物科技有限公司 抗疟原虫单克隆抗体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018193063A2 (en) * 2017-04-19 2018-10-25 Institute For Research In Biomedicine Novel malaria vaccines and antibodies binding to plasmodium sporozoites

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
NZ544924A (en) 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
GB0420634D0 (en) * 2004-09-16 2004-10-20 Glaxosmithkline Biolog Sa Vaccines
EP2158318A2 (en) 2007-05-14 2010-03-03 Biogen Idec MA, Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
PL2350128T3 (pl) 2008-10-22 2015-03-31 Inst Res Biomedicine Sposoby wytwarzania przeciwciał z komórek plazmatycznych
WO2011022002A1 (en) * 2009-08-18 2011-02-24 The Rockefeller University Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes
US8326547B2 (en) 2009-10-07 2012-12-04 Nanjingjinsirui Science & Technology Biology Corp. Method of sequence optimization for improved recombinant protein expression using a particle swarm optimization algorithm
CN103611151A (zh) * 2013-12-06 2014-03-05 广东药学院 疟原虫环子孢子蛋白多肽CSP I-plus 在制备抗疟疾药物中的应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018193063A2 (en) * 2017-04-19 2018-10-25 Institute For Research In Biomedicine Novel malaria vaccines and antibodies binding to plasmodium sporozoites

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KISALU, NK ET AL.: "A human monoclonal antibody prevents malaria infection and defines a new site of vulnerability on Pl", NATURE MEDICINE, vol. 24, no. 4, JPN6024013511, 2018, pages 408 - 416, ISSN: 0005432280 *
TAN, J ET AL.: "A public antibody lineage that potently inhibits malaria infection by dual binding to the circumspor", NATURE MEDICINE, vol. 24, no. 4, JPN6024013510, 2018, pages 401 - 407, XP038069543, ISSN: 0005432278, DOI: 10.1038/nm.4513 *
ZALEVSKY, J ET AL.: "Enhanced antibody half-life improves in vivo activity", NATUER BIOTECHNOLOGY, vol. 28, no. 2, JPN6024013512, 2010, pages 157 - 159, XP055308991, ISSN: 0005432279, DOI: 10.1038/nbt.1601 *

Also Published As

Publication number Publication date
SG11202108585QA (en) 2021-11-29
CA3130805A1 (en) 2020-11-05
US20230084102A1 (en) 2023-03-16
WO2020221451A1 (en) 2020-11-05
AU2020266283A1 (en) 2021-09-02
CN114206921A (zh) 2022-03-18
MX2021013252A (es) 2021-11-17
IL285282A (en) 2021-09-30
EP3962513A1 (en) 2022-03-09
KR20220004055A (ko) 2022-01-11
WO2020221910A1 (en) 2020-11-05
EA202192930A1 (ru) 2022-02-24
CN114206921B (zh) 2024-05-14
BR112021016341A2 (pt) 2021-10-26

Similar Documents

Publication Publication Date Title
JP6840908B1 (ja) エフェクター機能が除去されたＩｇＧ１ Ｆｃ変異体
TWI417299B (zh) 包括抗體、抗體衍生物及抗體片段之專一性地結合至ｃｄ１５４之結合蛋白及其用途
JP6138740B2 (ja) 細胞毒性免疫グロブリン
WO2022042690A1 (zh) Ccr8抗体及其应用
JP2019533427A (ja) アゴニズム及びエフェクター機能が増強した改変抗体、及び他のＦｃドメイン含有分子
JP2016509476A (ja) ヒトＩｇＧ１Ｆｃ領域変異体およびその使用
TW202039547A (zh) 中和ｂ型肝炎病毒之抗體和彼之用途
CN111183153A (zh) Cd3/cd33双特异性结合分子
JP2022531552A (ja) プラスモジウムスポロゾイト周囲タンパク質に結合する抗体、及びその使用
WO2020260315A1 (en) Deimmunized antibodies binding to alpha-4 integrin and uses thereof
US20250129142A1 (en) Antibodies binding to tetanus toxin and uses thereof
TW202417513A (zh) TGF-β-RII結合蛋白
JP2024514077A (ja) 切断したｔａｃｉポリペプチド及びその融合タンパク質並びに使用
US20250297026A1 (en) Therapeutic antibodies
US20240034772A1 (en) Antibodies binding to f-protein of metapneumovirus and uses thereof
HK40070165A (en) Antibodies binding to plasmodium circumsporozoite protein and uses thereof
OA20886A (en) Antibodies binding to plasmodium circumsporozoite protein and uses thereof.
KR20250059447A (ko) 항-ilt4 항체 및 이의 의약적 용도
CN116848133A (zh) 结合偏肺病毒f蛋白的抗体及其用途
WO2026008055A1 (zh) 抗kit抗体及其医药用途
TW202602945A (zh) 抗ｇｕｃｙ２ｃ抗體及其多特異性抗體的用途
EA052697B1 (ru) Антитела против ccr8 и их применение
TW202613160A (zh) 中和ｂ型肝炎病毒之抗體和彼之用途

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20220527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230414

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230414

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240705

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241008

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241225

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250430